TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (“NurExone” or the “Company“) (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top“), together with the Company, has signed a binding memorandum

TORONTO and HAIFA, Israel, July 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a bioprocess optimization initiative intended to support the manufacturing infrastructure for its therapeutic pipeline and commercial exosome activities.

TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds

TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement